Japan Tissue Engineering Co., Ltd. Logo

Japan Tissue Engineering Co., Ltd.

Pioneers regenerative medicine with tissue products, CDMO services, and research models.

7774 | T

Overview

Corporate Details

ISIN(s):
JP3389610001
LEI:
Country:
Japan
Address:
蒲郡市三谷北通6丁目209番地の1
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Japan Tissue Engineering Co., Ltd. (J-TEC) is a pioneering biotechnology company focused on the commercialization of regenerative medicine. The company operates through three primary segments: the Regenerative Medicine Business, which develops, manufactures, and sells tissue-engineered medical products such as autologous cultured cartilage; the Custom Development & Manufacturing (CDMO) Business, offering contract services for cell and gene therapy developers; and the LabCyte Business, providing cultured human tissue models for research and safety testing. A member of the Teijin Group, J-TEC was the first company to commercialize regenerative medicine in Japan and aims to establish it as a standard of care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:39
Registration Form
確認書
Japanese 8.3 KB
2025-11-13 07:37
Interim / Quarterly Report
半期報告書-第28期(2025/04/01-2026/03/31)
Japanese 190.7 KB
2025-06-19 10:05
AGM Information
臨時報告書
Japanese 27.0 KB
2025-06-19 07:20
Governance Information
内部統制報告書-第27期(2024/04/01-2025/03/31)
Japanese 21.7 KB
2025-06-19 07:18
Registration Form
確認書
Japanese 8.3 KB
2025-06-19 07:16
Annual Report
有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 920.6 KB
2024-11-13 06:09
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-11-13 06:07
Interim / Quarterly Report
半期報告書-第27期(2024/04/01-2025/03/31)
Japanese 188.4 KB
2024-06-19 07:50
AGM Information
臨時報告書
Japanese 22.1 KB
2024-06-19 07:48
Governance Information
内部統制報告書-第26期(2023/04/01-2024/03/31)
Japanese 21.5 KB
2024-06-19 07:46
Registration Form
確認書
Japanese 8.3 KB
2024-06-19 07:45
Annual Report
有価証券報告書-第26期(2023/04/01-2024/03/31)
Japanese 907.6 KB
2024-02-13 06:39
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-02-13 06:38
Quarterly Report
四半期報告書-第26期第3四半期(2023/10/01-2023/12/31)
Japanese 169.5 KB
2023-11-14 07:22
Report Publication Announcement
確認書
Japanese 8.3 KB

Automate Your Workflow. Get a real-time feed of all Japan Tissue Engineering Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Japan Tissue Engineering Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Japan Tissue Engineering Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.